| Submission | Oct. 30, 2024 |
| Submission [Line Items] | |
| Central Index Key | 0001438533 |
| Registrant Name | Travere Therapeutics, Inc. |
| Registration File Number | 333-281194 |
| Form Type | S-3 |
| Submission Type | 424B5 |
| Fee Exhibit Type | EX-FILING FEES |
| Offerings - Offering: 1 | Oct. 30, 2024 USD ($) |
| Offering: | |
| Fee Previously Paid | false |
| Rule 457(r) | true |
| Security Type | Equity |
| Security Class Title | Common Stock, par value $0.0001 per share |
| Maximum Aggregate Offering Price | $ 100,000,000 |
| Fee Rate | 0.01531% |
| Amount of Registration Fee | $ 15,310 |
| Offering Note | The Proposed Maximum Aggregate Offering Price is being used to calculate the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. The Amount of Registration Fee is calculated in accordance with Rule 456(b) and Rule 457(r) of the Securities Act of 1933, as amended. This "Calculation of Registration Fee" table shall be deemed to update the "Calculation of Registration Fee" table in the registrant's registration statement on Form S-3ASR filed with the Securities and Exchange Commission on August 1, 2024 (File No. 333-281194). |
| Fees Summary | Oct. 30, 2024 USD ($) |
| Fees Summary [Line Items] | |
| Total Offering | $ 100,000,000 |
| Previously Paid Amount | 0 |
| Total Fee Amount | 15,310 |
| Total Offset Amount | 0 |
| Net Fee | $ 15,310 |
| Final Prospectus | false |
